World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
114
Citations
53884
World Ranking
408
National Ranking
251

Medicine

D-Index
115
Citations
54145
World Ranking
4510
National Ranking
2451

Amit Bar-Or publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Amit Bar-Or sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 587 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Amit Bar-Or D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Amit Bar-Or sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 114 D-Index — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Amit Bar-Or is affiliated with the University of Pennsylvania in the United States and specializes in medical research, with a significant focus on multiple sclerosis and related neurological disorders. Their publication record includes over 400 works primarily in the field of medicine, with detailed contributions to pathology and forensic medicine, immunology, neurology, molecular biology, and oncology.

Their recent research outputs cover various facets of multiple sclerosis and immunological responses. Selected recent papers include:

  • Ofatumumab versus Teriflunomide in Multiple Sclerosis, 2020, New England Journal of Medicine
  • Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, 2021, Nature Medicine
  • Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis, 2020, Neurology
  • Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course, 2022, Cell
  • Role of B Cells in Multiple Sclerosis and Related Disorders, 2020, Annals of Neurology

The main topics of research covered in their work include:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Immunotherapy and Immune Responses
  • Polyomavirus and related diseases
  • SARS-CoV-2 and COVID-19 Research
  • T-cell and B-cell Immunology
  • Systemic Lupus Erythematosus Research

Frequent collaborators in their work include Douglas L. Arnold, Bruce Cree, Ludwig Kappos, Brenda Banwell, and Ruth Ann Marrie. These collaborations reflect a strong network in neurological and immunological research communities.

Publication venues where this scientist's research regularly appears include:

  • Neurology
  • Multiple Sclerosis Journal
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Multiple Sclerosis and Related Disorders
  • Journal of Neurology Neurosurgery & Psychiatry

Amit Bar-Or's scholarly focus integrates clinical and molecular perspectives on diseases primarily affecting the nervous system and immune regulation. Their work spans experimental and clinical studies, particularly emphasizing immune responses to therapies and vaccinations in conditions such as multiple sclerosis.

Best Publications

  • B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

    Stephen L. Hauser;Emmanuelle Waubant;Douglas L. Arnold;Timothy Vollmer

  • Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

    Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni

  • Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

    Ralf Gold;Ludwig Kappos;Douglas L Arnold;Amit Bar-Or

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Multiple sclerosis

    Unknown

  • IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

    Ping Shen;Toralf Roch;Vicky Lampropoulou;Richard A. O’Connor

  • Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    Unknown

  • Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

    Ludwig Kappos;David Li;Peter A Calabresi;Paul O'Connor

  • Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

    Martin Duddy;Masaaki Niino;Femina Adatia;Sherry Hebert

  • B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

    Tom A. Barr;Ping Shen;Sheila Brown;Vicky Lampropoulou

  • Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Stephen L. Hauser;Amit Bar-Or;Jeffrey A. Cohen;Giancarlo Comi

  • Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

    Amit Bar-Or;Peter A. J. Calabresi;Douglas Arnold;Clyde Markowitz

  • Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays

    P.J. Waters;A. McKeon;M.I. Leite;S. Rajasekharan

  • Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

    Amit Bar-Or;Lama Fawaz;Boli Fan;Peter J. Darlington

  • Comparison of polarization properties of human adult microglia and blood-derived macrophages

    Bryce A. Durafourt;Craig S. Moore;Domenick A. Zammit;Trina A. Johnson

  • Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

    Brenda Banwell;Angelo Ghezzi;Amit Bar-Or;Yann Mikaeloff

  • Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.

    Sokratis A. Apostolidis;Mihir Kakara;Mark M Painter;Rishi Raj Goel

  • Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

    Rui Li;Ayman Rezk;Yusei Miyazaki;Ellen Hilgenberg

  • Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

    Konrad Gabrusiewicz;Benjamin Rodriguez;Jun Wei;Yuuri Hashimoto

  • A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

    Jodie M Burton;Samantha Kimball;Reinhold Vieth;Amit Bar-Or

  • Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis

    Amit Bar-Or;Robert K. Nuttall;Martin Duddy;Andrea Alter

  • A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

    P W O'Connor;D Li;M S Freedman;A Bar-Or

  • Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?

    Martin E. Duddy;Andrea Alter;Amit Bar-Or

  • Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease

    Alon Monsonego;Victor Zota;Arnon Karni;Jeffery I. Krieger

Frequent Co-Authors

Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Jack P. Antel
Jack P. Antel McGill University
Brenda Banwell
Brenda Banwell Children's Hospital of Philadelphia
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Krzysztof Selmaj
Krzysztof Selmaj University of Warmia and Mazury in Olsztyn
Ralf Gold
Ralf Gold Ruhr University Bochum
Stephen L. Hauser
Stephen L. Hauser University of California, San Francisco
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Bruce A. C. Cree
Bruce A. C. Cree University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related online degrees can open diverse career pathways. Nursing offers a practical route, with programs like the nurse practitioner accelerated program providing an expedited path for aspiring practitioners. These programs allow students to transition quickly into advanced clinical roles.

Additionally, individuals without a nursing background can start with accessible programs such as online ADN programs for non nurses, which are designed to build foundational nursing skills from scratch. These online degrees offer flexibility and convenience for career changers.

For those looking to enter nursing efficiently, the easiest ABSN programs to get into provide straightforward admission processes without compromising educational quality. They serve as a solid foundation for careers linked to Immunology research and patient care.

Furthermore, starting with practical nursing credentials through easy admission LPN programs can be an effective stepping stone. Licensed Practical Nurses frequently support immunological healthcare teams, making this a viable initial pathway.

Best Scientists Citing Amit Bar-Or

Trending Scientists

Recently Published Articles